Last reviewed · How we verify
Stelara (ustekinumab)
Ustekinumab binds to the p40 subunit of IL-12 and IL-23, disrupting their signaling and reducing inflammation.
At a glance
| Generic name | ustekinumab |
|---|---|
| Sponsor | Johnson & Johnson |
| Target | p40 protein subunit of IL-12 and IL-23 |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| Annual revenue | 9500 |
Mechanism of action
Ustekinumab is a monoclonal antibody that targets the p40 protein subunit shared by IL-12 and IL-23 cytokines. By binding to this subunit, ustekinumab prevents these cytokines from interacting with their receptor, IL-12Rβ1, thereby blocking the inflammatory signals they normally transmit. This helps reduce the chronic inflammation seen in conditions like Crohn’s disease and ulcerative colitis.
Approved indications
- Crohn's disease
- Plaque psoriasis
- Psoriasis
- Psoriasis with arthropathy
- Ulcerative colitis
Common side effects
- nasopharyngitis
- upper respiratory tract infection
- headache
- fatigue
- back pain
- dizziness
- pharyngolaryngeal pain
- pruritus
- injection site erythema
- myalgia
- depression
Key clinical trials
- Acceptability and Therapeutic Maintenance of the Biosimilar Ustekinumab After Substitution (N/A)
- ROLL'YN-UST: Etude Observationnelle de Cohorte Pour la Prise en Charge Des Patients Atteints de Pathologies Inflammatoires Chroniques traités Par Steqeyma®, un Biosimilaire de l'ustékinumab (N/A)
- Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease (N/A)
- IBD Cancer and Serious Infection in Europe (N/A)
- BioTRAC (BIOLOGIC TREATMENT REGISTRY ACROSS CANADA) (N/A)
- Combining Biological Therapies in Patients With Inflammatory Bowel Disease: a Finnish Multi-centre Study. (N/A)
- Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease. (N/A)
- Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Re (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |